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Abstract
Bioactive glass (BAG) and clodronate are both used for bone regeneration. In this pilot clinical study, we 
compared the effect of BAG and a novel BAG+clodronate combination as a topical maintenance phase treatment 
for chronic periodontitis. 
Two dental residual pockets were treated in each subject (n=10): one with BAG alone and the other with 
combination product, by applying the products subgingivally for 10 min once a week for four weeks. We describe the 
effects of these investigational products to the clinical parameters of periodontitis and two bone metabolism markers 
(osteoprotegerin and osteocalcin). Additionally, subjective satisfaction for the treatment was evaluated. 
The results must be considered as directional, understanding that further investigation is needed to confirm the 
findings. Based on clinical parameters measured both treatments could benefit as maintenance therapy for chronic 
periodontitis. The positive effect of the combination product on tooth sensitivity may bring additional benefits in 
comparison to the use of BAG alone. Both treatments were well tolerated and safe.
Keywords: Bioactive glass; Clodronate; Periodontitis
Abbreviations: BAG: Bioactive Glass; BAG+C: Combination of 
Bioactive Glass and Clodronate; BOP: Bleeding on Probing; COX-2: 
Cyclooxygenase-2; F: Follow-Up Visit; GCF: Gingival Crevicular Fluid: 
min: Minute; OPG: Osteoprotegerin; OC: Osteocalcin; PAL: Probing 
Attachment Level; PPD: Probing Pocket Depth: TV: Treatment Visit; 
VAS: Visual Analog Pain Scale; VPI: Visible Plaque Index
Introduction
Periodontitis is a reversible condition that, if left untreated, may 
develop into chronic periodontitis, as plaque induced gingivitis extends 
from the gingiva and leads to irreversible progressive loss of alveolar 
bone and periodontal ligament attachment. Ultimately, periodontitis 
can cause tooth loss. In periodontal disease the height of alveolar bone 
is lower which results in deeper pockets [1]. The aim of periodontitis 
therapy is to reduce gingival inflammation, reduce pocket depth as 
well as bone loss and increase attachment to gingiva. Usually this can 
be accomplished by non-surgical means with mechanical removal of 
the bacterial biofilm and their toxins from the tooth surface making it 
compatible with biologic reattachment that is the basis of any eventual 
adjunctive therapy. Both surgical and non-surgical periodontal 
treatments result in recession of the gingival margin after healing. 
Localized recession and root exposure is often associated with dentin 
hypersensitivity [1-4]. The maintenance phase of periodontal therapy 
is defined as the maintenance of periodontal health following active, 
primary treatment of periodontitis in order to achieve long-term 
stability of results and to minimize recurrence. Currently there is no 
established medical treatment for periodontitis maintenance phase, 
which would help in reducing pocket depth as well as bone loss and 
increase attachment to gingiva.
Bioactive glass (BAG, Na2O-CaO-P2O5-SiO2) has been used for 
long time as a bone cavity-filling material in the cranio-maxillofacial 
area (e.g. frontal sinus obliteration after severe chronic sinusitis), in 
orthopedics, and in the treatment of osteomyelitis [5-7]. During the 
last two decades, its use has expanded into dentistry, for instance, 
for treating cortical bone defects [8] and hypersensitive teeth [4,9]. 
There are obvious similarities between bone and dentine concerning 
their metabolism. BAG is potentially useful as a means of stimulating 
remineralization of the upper layer of the tooth and protecting the tooth 
against alterations of temperature, pressure, solute concentrations, and 
local irritation [4,9]. BAG is known to have bacterial growth-inhibiting 
properties [7,10] and this could provide even more advantages in 
the treatment of periodontitis, i.e., infection-induced inflammation-
regulated degradation of tooth-supporting tissues. Moreover, the 
combination of bisphosphonates with bioactive glass provides protection 
against biofilms formed by the periodontal pathogen Aggregatibacter 
actinomycetemcomitans [11].
Clodronate is a bisphosphonate and although intravenously 
administered systemic bisphosphonate therapy can have a negative 
side effect, namely osteonecrosis of the mandibule [12], systemically 
administered bisphosphonate therapy seems to have beneficial effects 
on the periodontium: less plaque accumulation, gingival inflammation 
and periodontal attachment loss, lower probing depths, and greater 
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Eur.) was supplied by PharmaZell GmbH, Raubling, Germany. It was in 
the form of disodium salt (CH2Cl2O6P2Na2 4H2O 360.9 g/mol). 
Based on pre-formulation studies the combination of 200 mg 
clodronate and 1 g BAG with particle size 0.5-0.8 mm was proven as the 
most promising formulation for dental application to treat periodontitis 
[19]. Therefore, this was chosen as the test product, BAG+C, while the 
comparator product was 1 g BAG, both with 900 µl of 0.9% saline added. 
The final, paste-like, preparation of the study products was done during 
the same day as the products were applied into the selected periodontal 
pockets at the study clinic.
Study design and subjects
A total of 10 eligible, consenting study subjects, either men or 
women, were recruited to the investigation. According to the inclusion 
criteria, a subject had a diagnosis of chronic periodontitis as defined by at 
least two sites with probing pocket depth (PPD) ≥ 5 mm interproximally 
and had received conventional, anti-infective, mechanical treatment for 
the disease, but still had at least two residual periodontal pockets. The 
exclusion criteria were as follows: concurrent disease or condition that, 
in the opinion of the investigator, was contraindicating participation, 
simultaneous participation in another medical device or investigational 
drug trial, systemic antibiotic treatment, and smoking. According to 
the study protocol that is illustrated in Figure 1, the periodontal status 
was re-evaluated 4-6 weeks after mechanical, primary treatment. Two 
residual pockets with PPD of 4-6 mm, involving an identical tooth type 
and site, were selected for investigational product application. Eligible 
study subjects were provided first with a detailed information letter. 
One week later, at the enrolment visit, the volunteers gave their written 
consent. Additionally, baseline data and measures, including GCF 
sampling from two selected tooth sites, were performed before the first 
treatment (BAG+C and BAG) application. The study included a total of 
four treatment visits (TV1-TV4); once per subsequent week, BAG+C 
was applied into one residual pocket and BAG into the other pocket for 
10 min and left subgingivally. In this way, the subjects acted as their own 
comparator and control. In addition, the study included two follow-up 
visits; the first follow-up visit (F1) occurred one week and the second 
visit (F2) five weeks after the last treatment visit (=TV4, the last product 
application). Thus, the duration of the study was about two months for 
a single participant. 
Outcome measures
At the enrolment visit, the following data were recorded: age, gender, 
ethnic origin, and body mass index, information on relevant previous 
and current disease (medical history), smoking history, and alcohol 
consumption. Throughout the investigation, periodontal status at the 
tested sites was recorded comprising the following clinical parameters: 
visible plaque index (VPI), bleeding on probing (BOP) dichotomously 
(present/absent), PPD (probing pocket depth i.e., the distance between 
the gingival margin and the bottom of the pocket), gingival recession (the 
distance between the cemento-enamel junction and the gingival margin) 
and probing attachment level (PAL, i.e., the amount of attachment loss; 
derived from PPD and gingival recession) in millimeters measured with 
a WHO probe. Furthermore, at each visit, tooth sensitivity to air blow 
and cold water spray was examined and recorded by using visual analog 
pain scale (VAS; 0=no pain, 10=worst pain). From TV2 onwards, the 
participants were asked to evaluate possible changes (better, unchanged, 
or worse) in tooth function (subjective sensation and treatment success) 
with the treated sites compared to the situation at their previous visit 
and to appraise current overall satisfaction with the scale: excellent 
(1), good (2), satisfactory (3), or poor (4). As a safety variable, adverse 
alveolar bone levels [13]. Additionally, there is information available 
suggesting bone formation when using the combination of BAG and 
bisphosphonate administered locally in surgery as a filling material of 
bone defects [14,15].
The activity of cells involved in bone turnover can be assessed 
using chemical biomarker measurements from body fluids. This can 
be useful to determine the effectiveness of the treatment. There are 
several biomarkers that describe bone turnover and they can be divided 
into those indicating bone resorption or formation. Osteoprotegerin 
(OPG) is a good biomarker for bone resorption and bone loss [16] and 
osteocalcin (OC), in turn, indicates bone formation [17]. In the present 
study, these two biomarkers were chosen to be measured from gingival 
crevicular fluid (GCF).
Recently, it has been shown that clodronate enhances the bioactivity 
of BAG and keeps this effect ongoing longer than what is observed for 
BAG alone [18]. Based on experiment done by Rosenqvist and co-
workers [18], it is apparent that there is a strong interaction between 
BAG and clodronate resulting in an enhanced ion exchange. The 
interaction seems to be such that an extended ion exchange between 
the BAG and clodronate results in a layer of calcium clodronate on the 
surface of the bioactive glass. The formed layer includes also calcium 
phosphate [19]. Most importantly, the understanding is that clodronate 
enhances the bioactivity of bioactive glass and both calcium clodronate 
precipitation and apatite are formed. Therefore, the combination of BAG 
and clodronate (BAG+C) could have the potential to support locally the 
bone formation and be beneficial also in periodontal applications and 
be established treatment for periodontitis maintenance phase, which 
we currently lack. So far, no published data exist on the topical use of 
clodronate in the treatment of periodontal disease or on the use of the 
BAG+C combination as a clinical application. Within this background, 
the aim of the present preliminary pilot study was to investigate the effects 
of the combination product, namely BAG+C, on periodontal residual 
pockets and to compare the results on those of BAG alone. In order 
to investigate this, the experiment included measurements of clinical 
parameters, representing signs and symptoms of periodontitis, and bone 
metabolism markers in GCF. In addition, subjective assessment of tooth 
function and overall satisfaction for the treatment were recorded during 
the study. 
Materials and Methods
Study conduct and ethics
This pilot, open single-centre, comparative clinical investigation was 
conducted at the Institute of Dentistry, University of Turku, Finland, 
according to the clinical investigation plan, International Organization 
for Standardization: Clinical investigation of medical devices for human 
subjects-Good clinical practice (ISO 14155), European Union Directive: 
Good Clinical Practice and Helsinki Declaration. The ethical approval 
was obtained from the ethics committee of the Hospital District 
of Southwest Finland and the study was reported to the National 
Supervisory Authority for Welfare and Health in Finland.
Investigational study products: Bioactive glass (BAG) and 
clodronate
Bioactive glass (S53P4), BonAlive™, is a CE-marked product 
(medical device with marketing authorization in EU) by the BonAlive 
Biomaterials Ltd, Turku, Finland. The BonAlive™ product contains four 
oxides, SiO2 53%, Na2O 23%, CaO 20%, and P2O5 4% w/w. It is composed 
of amorphous odourless white granules with a particle size of 0.5-0.8 
mm, having the density of 2.66 g/cm3. Clodronate (Lot No T07/009 Ph. 
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events and device effects were collected starting from the screening and 
throughout the investigation. Additionally, all concomitant medications 
and treatments with the reason to administer were recorded during all 
visits.
GCF sampling, biomarker and data analysis
GCF samples were collected three times, at baseline and during FI 
and F2. After removing supragingival plaque and avoiding any saliva 
contamination, GCF sampling was performed by placing a paper strip 
into the selected residual pocket for 30 s. Any paper strip containing 
blood was discarded. The samples were placed into the Eppendorf 
tubes, which were stored at -20°C until assayed. The GCF samples were 
analyzed for two bone remodeling biomarkers, OPG and OC, by using 
a commercially available kit (Milliplex HBN1A-51K Osteoprotegerin/
Osteocalcin, Merck Millipore, St. Charles, Missouri, USA) according to 
the manufacturer’s instructions. The primary analysis population was 
a full analysis set, which included all study subjects. For the statistical 
analyses within the group, the 2-tailed Wilcoxon signed ranks tests and 
between two groups the Mann-Whitney U test were used. No imputation 
procedures were applied on missing data. The statistical significance was 
set at p value<0.05. Because the number of samples/data is limited, it 
needs to take notice of that, even the statistical analyses were performed, 
the result can be considered only as directional.
Results
Study subjects
Eight out of the 10 study subjects were men. The mean age of 
participants (all Caucasian) was 66.5 years and their mean body 
mass index was 26. Six subjects were former smokers. Two subjects 
had medication for hypercholesteremia and hypothyreosis; one had 
medication for prostate hyperplasia, one for hyperactive urinary 
bladder, and one for menopausal symptoms, while five subjects did 
not use any ongoing medications. Seven subjects participated at all 
scheduled visits and eight completed all follow-up visits. One subject 
discontinued prematurely after TV1 because of an adverse event (Figure 
1). One subject was unable to attend a treatment visit and the other one 
a follow-up visit. 
Clinical parameters 
PPD values reduced significantly in BAG+C and BAG treated teeth 
during the study (Figure 2a), while no differences in VPI or BOP values 
were observed. Gingival recession (the apical movement of the gingival 
tissue boundary) increased significantly for both treatment options from 
the baseline to F2 (Figure 2b). PAL decreased significantly in BAG+C 
treated teeth at both F1 and F2 as compared to the baseline (Figure 2c), 
whereas in BAG treated teeth the significant result was seen only at F2.
Biomarkers 
There was a significant change in the amount of OPG in BAG 
treated teeth at both follow-up visits when compared to the baseline 
value (Figure 3), while in BAG+C teeth there was a significant reduction 
in the amount of OPG only between the baseline and F2. A significant 
difference was observed between the treatment options at F1 when 
teeth treated with BAG had lower OPG levels than those treated with 
BAG+C. OC values remained at low levels throughout the study in both 
treatment options. 
Subjective sensation, treatment success and safety
Starting from TV2, the subjects were asked for change in the tooth 
function (better, unchanged, or worse) since the previous visit. There 
were no differences between the treatment options up to F2. There was 
one subject who estimated BAG+C better and one subject vice and 
versa, while other subjects considered both treatment options equal (the 
median value was “unchanged”). At F2, the subjects reported the tooth 
function to be slightly better in teeth treated with BAG+C (median: 
Figure 1: The flow chart presenting the study protocol. Treatment visit (TV) and follow-up visit (F).
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BAG+C better vs. BAG unchanged). Concerning hypersensitivity of the 
treated teeth, tested by air blow and cold water, all subjects estimated 
the pain to be less for BAG+C treated teeth than for BAG alone at F2.
At each visit, the mean value for overall satisfaction of treatment 
was reported slightly better for BAG+C treated teeth, although the 
median value was similar for both treatment options (Table 1). During 
the both follow-up visits, the overall satisfaction for BAG+C treated 
teeth varied from excellent to good and for BAG treated teeth from 
excellent to satisfactory (F1) or even poor (F2). 
There was only one adverse event recorded during the study; one 
subject had a mucosal lesion at the gingival area of a BAG+C treated 
tooth after the first application that led to the premature termination of 
the study. The situation was recovered within a month. Otherwise both 
treatment options were well tolerated and there were no safety issues 
reported.
Discussion
The novel combination product, BAG+C, was tested in a clinical 
pilot study, where its effects were compared to those of BAG alone at 
periodontal maintenance phase, without compromising the safety of the 
subjects. Since both BAG and clodronate separately are known to have 
beneficial effects to bone (e.g. stimulating the bone formation), there 
is a reason to believe that their synergistic effect is even better. BAG 
is known to be safe in clinical use, however, no combination product 
with bisphosphonates and BAG has been previously studied. Moreover, 
there is no published investigation about bisphosphonates used in 
the local treatment of deepened pockets at periodontal maintenance 
phase. Although our findings did not differ significantly between the 
given treatment options in general, looking at the investigated variables 
together, like PPD, OPG, change in tooth function, pain sensation after 
cold water and air blow, as well as overall satisfaction for treatment, the 
BAG+C product appeared to have a little better results than BAG alone. 
Indeed, the slightly better results in variables, especially the subject´s 
Figure 2: Probing pocket depth (PPD) (a), gingival recession (b) and probing 
attachment level (PAL) (c) in the test (bioactive glass and clodronate, BAG+C) 
and control (bioactive glass, BAG) site at baseline (n=10), first follow-up visit 
(F1; n=8) and second follow-up visit (F2; n=8). The box blots present the 
median (horizontal line), quartiles (boxes) and non-outlier values (whiskers). 
Statistical significance *p<0.05, **p<p<0.01
Figure 3: Total amount of osteoprotegerin in collected (gingival crevicular fluid) 
GCF (pg/30 s) from the test (bioactive glass and clodronate, BAG+C) and 
control (bioactive glass, BAG) site at baseline (n=10), first follow-up visit (F1; 
n=8) and second follow-up visit (F2; n=8). The box blots present the median 




Mean  Median (min-max) Mean Median (min-max)
TV2 (n=10) 2.4  2 (2-4) 2.5  2 (2-4)
TV3 (n=9) 2.11 2 (2-3) 2.33 2 (2-4)
TV4 (n=8) 2 2 (1-3) 2.25 2 (1-4)
F1 (n=8) 1.88 2 (1-2) 2 2 (1-3)
F2 (n=8) 1.88 2 (1-2) 2.13 2 (1-4)
Total (n=8) 2.05 2 (1-4) 2.24 2 (1-4)
Table 1: Mean and median score for study subject’s (n=number of subjects) 
evaluation for the situation (excellent (1), good (2), satisfactory (3), poor (4)) 
compared to that at previous visit in teeth treated with either combination product 
of bioactive glass and clodronate (BAG+C) or bioactive glass (BAG) alone 
(TV=treatment visit; F=follow-up visit).
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own feeling, indicate that adding clodronate to BAG may enhance the 
already known favorable effects of BAG alone. 
Based on published data, it is well defined that BAG has several 
beneficial effects in dental use [8-10]. In addition, it also improves the 
outcome in the given indication, i.e., periodontitis maintenance phase. 
This includes the advantageous effects of BAG on periodontal clinical 
signs, such as decreased PPD and increased clinical attachment level. 
These studies were done with an appropriate control arm [20,21]. A 
recent meta-analysis, summarizing results from randomized controlled 
clinical trials on the effect of BAG as a graft material in the treatment of 
periodontal intrabony defects, supports this information [22]. Indeed, 
BAG proved to be superior compared with other graft materials as well 
as with open flap debridement, seen as a considerable improvement 
in PPD and clinical attachment levels. Therefore, in the present study, 
the teeth treated with BAG alone served as a positive control group for 
the teeth treated with the test combination product BAG+C. Our study 
also proved BAG to be useful for the treatment of residual pockets at 
periodontal maintenance phase.
In the current literature, there are several animal studies on the 
potential of using bisphosphonates for the management of periodontitis 
or preventing root resorption when moving teeth by orthodontic means. 
In an experimental study on periodontitis in rats, Mitsuta et al. [23] 
suggested that the local administration of clodronate may be effective 
in preventing osteoclastic activity leading to bone resorption, which is 
the main characteristic of periodontitis. Another bisphosphonate agent, 
alendronate, was examined in a beagle dog model for its capability of 
inhibiting alveolar bone loss [24]. In the alendronate group, a significant 
increase in bone mass was observed compared to placebo groups. In a 
rat study by Yaffe et al. [25], where local delivery of alendronate was 
used together with tetracyclines, a combined effect was demonstrated 
in the reduction of alveolar bone loss. Furthermore, as a potent blocker 
of bone resorption, risedronate has been examined in the context of 
orthodontic tooth movements in rats [26]; it was suggested that the 
local administration of risedronate has favorable effects by preventing 
root resorption. 
There are some published data available about the use of combination 
of bisphosphonate and BAG as a local treatment. Välimäki et al. [14] 
examined the effect of subcutaneously administered zoledronic acid 
and BAG as a bone graft substitute in rat tibia. They conclude that 
the beneficial effect of bisphosphonate therapy may extend to healing 
of implants with bioactive hydroxyapatite coatings. In another case, 
where the combination of alendronate and BAG was studied in the rat 
mandible as a filling material of a created bone defect, the combination 
proved to induce bone regeneration and was thus considered to be 
useful for alveolar ridge augmentation followed by dental implant 
surgery and for bone regeneration in periodontal defects [15].
Of the two bone remodeling biomarkers selected for the present 
study, OPG data indicate that the effect of the combination product 
(BAG+C) is slightly better than the effect of BAG alone. However, due 
to the short time period of investigation as well as the limited number 
of subjects and treated teeth, the result remains only indicative. OPG 
is known to inhibit the differentiation activity of osteoclasts (bone 
resorbing cells) by blocking ligand RANK (RANKL, receptor activator 
of nuclear factor-kappa B for osteoclast precursor cell), which is a good 
biomarker for bone resorption and bone loss [16]. Bisphosphonates 
cause osteoblasts (bone forming cells) to release OPG [27]. Clodronate 
is known to inhibit osteoclast activity through apoptosis [28] and, 
further, COX-2 dependent prostaglandin E2 production and RANKL 
expression in periodontal ligament cells [29]. The biomarker needs 
to clearly reflect the variable of interest, e.g. bone resorption and be 
specific and sensitive enough. In these published studies listed above, 
the release of OPG was examined from sites with nitrogen containing 
bisphosphonates, the possible effect for decreased bone degradation 
may not be seen so clearly in our investigation using OPG as a biomarker 
as clodronate is not nitrogen-containing bisphosphonate. On the other 
hand, decreased OPG levels could indicate that bone turnover was 
activated, because in order to have bone formation there is need to have 
also resorption. However, in that case the bone formation marker OC 
should have demonstrated more activity. Bone metabolism processes 
are slow and do not happen in weeks. Therefore, it might be that our 
biomarker results describe the early phase of the treatment success 
and the later part was still to come. Although it is known that BAG 
releases ionic products and enhances the expression of osteogenic 
markers like OC [17], we failed to demonstrate any change at OC levels. 
In a way, this could be a good sign, if interpreted that neither of the 
investigated treatments decreased the activity of osteoblasts as such. 
Both OPG and OC are regulated and effect mediated via osteoblasts 
[16,17]. As clodronate mostly has an influence on osteoclasts and 
BAG on osteoblasts, it might be that both selected biomarkers reflect 
mostly the effect of BAG, not that of BAG+C, i.e., the benefit of having 
clodronate in the combination product. This could explain why OC 
levels did not differ between the products and the change in OPG levels 
was only minor. Therefore, in future studies also other bone turnover 
biomarkers, such as osteopontin, osteonectin and bone sialoprotein, 
should be considered. Moreover, radiological examination after a 
longer follow-up period than two months could give more information 
about the quality of bone. In our pilot study, the patients were protected 
from exposure to radiation.
In the present study, the subjects were asked for their opinion about 
the tooth function and hypersensitivity in the treatment area, and 
overall satisfaction. The outcome in BAG+C treated teeth was better 
than that in BAG treated teeth. Based on results of clinical signs and 
biomarkers, both treatment options can be considered equally good. 
Copay et al. [30] reviewed the dilemma, whether the difference in 
clinical parameters or the subjective outcome is more important from 
the patient’s point of view. They conclude that, even though the general 
concept for this is lacking, the self-reported outcomes should have more 
value and be distinguished from objective clinical measures. Therefore, 
with caution, we suggest that the subject’s self-reported results can be 
considered to verify that BAG+C is slightly better than BAG alone in 
the treatment of residual pockets at periodontal maintenance phase.
The limitations of our study include the limited number of participants, 
rather few applications of test and control agents, and a relatively short 
follow-up period. Compared to earlier investigations done with BAG, for 
example, Biosilicate® (fully crystallized bioactive glass) in the treatment of 
hypersensitive teeth [9], the treatment was given twice daily for 30 days. 
Therefore, it was surprising that with this limited amount of applications, 
our study gave such good results. In addition, reduced pain scores were 
similar to those observed in the study by Tirapelli et al. [9] and the 
reduction in pain remained up to the completion of follow-up visits. The 
study duration and number of applications of tested agents were kept in 
minimum, because the combination product (BAG+C) was used for the 
first time in a clinical setting. 
The only adverse event in the present study, the mucosal lesion 
close to a tooth treated with BAG+C, did not appear right after the 
application of the agent. Therefore, it is not clear whether it was caused 
by the tested agent or whether there was an injury, such as too intense 
tooth brushing, behind the event.
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Conclusion
Our results indicated that the novel combination product BAG+C 
is, at least, as beneficial as BAG alone in treating residual pockets at 
the periodontal maintenance phase. In addition, the combination 
product decreased subjective sensitivity symptoms slightly more than 
the control product, thus, subjects may find BAG+C as a satisfactory 
treatment option. These findings are promising but understanding the 
limits of our investigation, further research is needed before suggesting 
its use in clinical practice.
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